Lfcr investor alert: robbins geller rudman & dowd llp announces that lifecore biomedical, inc. investors with substantial losses have opportunity to lead class action lawsuit

San diego, aug. 01, 2024 (globe newswire) -- robbins geller rudman & dowd llp announces that purchasers or acquirers of lifecore biomedical, inc. (nasdaq: lfcr) securities between october 7, 2020 and march 19, 2024, both dates inclusive (the “class period”), have until september 27, 2024 to seek appointment as lead plaintiff of the lifecore biomedical class action lawsuit. captioned carew v. lifecore biomedical, inc., no. 24-cv-03028 (d. minn.), the lifecore biomedical class action lawsuit charges lifecore biomedical and certain of lifecore biomedical's top current and former executives with violations of the securities exchange act of 1934.
LFCR Ratings Summary
LFCR Quant Ranking